In addition to being a service provider, ITG is involved in the development of its own proprietary technologies.

ITG, in collaboration with the Gabriel Institute and Valco Instruments Company, Inc. has developed a novel method to treat solid inoperable tumors.  Traditional brachytherapy uses encapsulated gamma emitters and irradiation of non-target tissue is a big issue.  Beta emitters, which would have a much smaller field of irradiation, have not been used in this manner because the capsules would effectively shield the beta particles.  Use of beta emitters without encapsulation would normally result in the migration of isotope and thus radiation dose to non-target tissues.  Liquid Brachytherapy involves a simple and effective chemical approach to immobilizing metallic radioisotopes.  This technology is protected by PCT patent application WO 2009/045230. This technology is available for license.

ITG has developed a novel methodology for the treatment of severe arthritis and other conditions of synovitis.  In one manifestation of the technology, magnetic nanoparticles are injected into the synovial space of an affected joint and the particles are allowed to be phagocytized by the synovial membrane.  An external stimulus such as an alternating magnetic field is applied causing the particles to heat and thermally destroy the diseased tissue.  The only tissues affected are those where the particles and the external stimulus are coincident.  This technology is protected by PCT patent application WO 2008/060393 .  ITG is currently in negotiations with a potential partner for this technology.

ITG has developed a novel radiopharmaceutical for the treatment of bladder cancer.  This systemically administered material clears very rapidly into the urinary bladder thus delivering a therapeutic radiation dose to the bladder wall.  Dosimetry calculations predict minimal radiation dose to other tissues.  This technology is protected by PCT patent application WO 2007/126730.  This technology is available for license.